Pfizer's Differentiation Strategy in the MNC Innovation Center Boom: Building a Smart Healthcare Ecosystem Beyond the Pill

Another Major Player Joins the Ranks of MNCs’ Innovation Centers in China

On November 30, 2023, the “Pfizer Smart Healthcare Innovation Center” was grandly inaugurated in Qiantang District, Hangzhou. The center focuses on exploring medical innovations empowered by cutting-edge technologies and strengthening collaboration with government bodies, ecosystem enterprises, research institutes, and other industry stakeholders, jointly delivering higher-quality, smarter innovative healthcare solutions for physicians and patients.

This is Pfizer’s first Smart Healthcare Innovation Center established in China, marking a significant strategic move to deepen digital innovation and empower the healthcare industry.

Less than a year later, the phased achievements of Pfizer’s smart healthcare innovation deployment are gradually becoming evident.On September 24, at the 2024 “Tide Rising in Qiantang” Smart Healthcare Innovation Ecosystem Conference and the Second Symposium of the Smart Healthcare Advisory Committee to be held in Hangzhou, Pfizer will make a major announcement of its Smart Healthcare Innovation Ecosystem, kick off the signing of a Memorandum of Understanding (MoU) for strategic cooperation with Zhejiang University, and showcase the first batch of ecosystem enterprises established at China Medicine Port.

This conference was guided by the Administrative Committee of Qiantang New Area, Hangzhou, hosted by Pfizer China, and co-organized by the Commerce Bureau of Qiantang District, Hangzhou, the Health Administration Bureau of Qiantang District, Hangzhou, and the Office of Hangzhou Medicine Port.

Based on the conference agenda and guest lineup, Pfizer will build a platform for ecosystem communication, collaboration, and matchmaking to connect with more policy departments, research institutes, tech giants, and innovative startups. Together, they will explore innovative models of smart healthcare, pool innovative resources, and establish a regional industrial hub.

As is well known, the introduction of numerous biopharmaceutical policies, such as the consistency evaluation and volume-based procurement, has had a significant impact on China’s pharmaceutical market environment. Many multinational corporations have begun to adopt digital strategies as key measures to empower their internal value chains and drive business growth. Pfizer, which relies on innovation as the driving force for its corporate development, has also demonstrated great enthusiasm for digital exploration.

Prior to the establishment of its Smart Healthcare Innovation Center, Pfizer explored digital innovation across the entire business spectrum—including AI-driven drug discovery, data management, digital marketing, and patient empowerment—through in-house development, collaborations, and investments. This approach has provided large pharmaceutical companies with new perspectives on digital innovation, bridging theory and practice.

From observations over the past year,Pfizer is upgrading its “smart healthcare” and even “digital-intelligent healthcare” initiatives, building on its existing digital infrastructure.

Jean-Christophe Pointeau, Senior Vice President of Pfizer Global and President of Pfizer China, stated in a public interview that Pfizer is not only dedicated to the research, development, and manufacturing of innovative medicines but also committed to providing “beyond the pill” digital solutions. By developing patient-centric digital management tools that offer disease management and health education, Pfizer aims to enhance patients’ treatment experiences and further improve the overall health outcomes of the patient population.

The moves of industry giants always serve as significant bellwethers. VCBeat attempts to outline the underlying logic of Pfizer’s Smart Healthcare Innovation Center, drawing from Pfizer’s public materials and industry exchanges, for the reference of the healthcare sector.

VCBeat believes that, compared with digital healthcare, which focuses on improving the efficiency and quality of medical services through digital means, “Smart Healthcare” emphasizes the intelligence and connectivity of healthcare systems to achieve optimized allocation of medical resources. “Digital-Intelligent Healthcare,” on the other hand, represents a further upgrade built upon digitalization and smartification. By integrating more cutting-edge technologies such as big data analytics and generative AI, it not only achieves higher medical efficiency and convenience but also emphasizes the deep mining of the value of medical data and its personalized, precise application.

So, how is Pfizer’s “smart” and “digital-intelligent” upgrade manifested?

From a macro perspective, driven by the wave of digital transformation and the increasingly diversified and personalized demands of patients for medical services, pharmaceutical companies need to provide more precise, efficient, and convenient healthcare innovation solutions. Focusing on Pfizer, its independent development of underlying digital technology platforms can further consolidate its technological advantages in drug R&D, manufacturing, and supply chain management. This also helps Pfizer achieve standardization and intelligence in business processes, thereby reducing costs and improving efficiency.

“The development of digital innovation technologies and platforms” has thus become one of the key business areas of Pfizer’s Smart Healthcare Innovation Center., Pfizer’s Smart Healthcare Innovation Center has also established a dedicated technology development team that delivers technical solutions by addressing real-world clinical challenges through in-house development, joint ventures, or external collaborations. This not only demonstrates its financial strength, technological reserves, and management capabilities, but also underscores Pfizer’s determination and confidence in advancing and upgrading foundational technology research and development.

In traditional medical content production, medical content is typically authored by experts with profound professional knowledge, resulting in high entry barriers, substantial labor costs, and time-consuming processes. In contrast, AIGC technology has demonstrated significant application value in this field.

AIGC technology can generate medical content more efficiently and in a customized manner based on the personalized needs of different target audiences. For instance, for physicians who prefer to quickly grasp core information, it can directly extract and precisely present key conclusions. In the realm of medical science popularization, AIGC technology also empowers pharmaceutical companies to rapidly and efficiently produce diverse and in-depth academic promotional materials, significantly enhancing content productivity.

However, the maturity of AIGC technology applications is closely tied to factors such as the richness of training corpora, deep understanding of the healthcare industry, advanced algorithmic architectures, and effective feedback mechanisms. Acquiring these resources poses a significant challenge for technology companies.

Pfizer possesses unique resources in this regard: deep medical insights accumulated through long-term drug development, clinical trials, and medical practice; robust R&D capabilities built upon a strong scientific research team and advanced technological infrastructure; as well as mature clinical experience and feedback mechanisms. By collaborating with ecosystem partners, the Pfizer Smart Healthcare Innovation Center leverages AIGC technology to generate high-value medical content for Pfizer while achieving cost reduction and efficiency improvement.

It is important to note that although AIGC technology demonstrates significant potential, it currently lacks the capability to “comprehensively address medical content creation,” such as establishing various medical content editing templates and conducting content reviews for complex and sensitive materials.

Therefore, Pfizer aims to collaborate with ecosystem partners through a model of “AIGC technology + specialized teams” to establish an “Intelligent Medical Content Factory,” thereby achieving a virtuous cycle in medical content management—from data insights, content creation, approval, and management, to distribution, and back to data insights.

Driven by factors such as rising economic standards, heightened health awareness, and the iterative advancement of digital technologies, patients’ health needs have shifted from “disease treatment” to “full-cycle health management.” As a patient-centric organization, Pfizer has accordingly defined the third strategic direction for its Smart Healthcare Innovation Center: developing innovative solutions tailored to healthcare providers and patients. By leveraging cutting-edge technologies, Pfizer aims to create innovative models and solutions that address the distinct stages of diagnosis and treatment for both physicians and patients. Focusing on Pfizer’s key therapeutic areas—including oncology, anti-infectives, inflammation and immunology, and migraine—the company is committed to delivering digital solutions across various scenarios and channels throughout the patient journey. These efforts aim to improve patients’ access to high-quality medical resources and enhance the efficiency of healthcare services.

Given the complexity and diversity of medical innovation, the development of both digital health and the biopharmaceutical industry is no overnight feat. First, medical innovation often involves high-risk technological R&D and clinical trials, requiring substantial financial support. Second, technologies and policies in the healthcare sector are constantly evolving; the emergence and application of new technologies require time for validation and widespread adoption. Therefore, industrial development demands active collaboration among all stakeholders—including government, industry, academia, research institutions, healthcare providers, and investors—to ultimately create an ecosystem that fosters a virtuous cycle of innovation.

In this regard, Wang Fei, General Manager of the Pfizer Smart Healthcare Innovation Center, has stated thatIn the future, the Pfizer Smart Healthcare Innovation Center will also serve as an incubator for cutting-edge smart healthcare innovation projects., by leveraging internal synergy and external collaboration, to jointly incubate and develop professional digital healthcare products and services.

At this point, the business direction of Pfizer’s Smart Healthcare Innovation Center has come into focus, namely to concentrate onDevelopment of innovative technologies and platforms, delivery of professional medical content, creation of innovative models for patients and healthcare providers, and incubation of ecosystem partnershipsFour Key Directions: Empowering Healthcare Services with Advanced Technology.

From a global perspective, the development of any industry is inseparable from a region that possesses industrial cluster advantages and deep collaborative capabilities, such as Silicon Valley for semiconductors and Hangzhou Qiantang for biopharmaceuticals.

As the core hub of Hangzhou’s biopharmaceutical industry, Qiantang District is driving the “integration of six chains”—namely, the innovation chain, industrial chain, talent chain, policy chain, financial chain, and service chain—to continuously gather innovative elements for its biopharmaceutical sector.

Home to the Hangzhou Medical Port, established six years ago, the area has gathered more than 1,700 biopharmaceutical companies, primarily focusing on innovative drugs, high-end medical devices, and digital health. It currently hosts 23 listed and pre-IPO companies, as well as 31 Hangzhou “quasi-unicorn” enterprises, accounting for nearly one-third of all such companies in Hangzhou. Seven of the world’s top ten pharmaceutical giants, including Pfizer, Merck & Co., and Abbott, have also established a presence here. According to the development plan, by 2026, the Hangzhou Medical Port aims to achieve RMB 100 billion in main business revenue from the biopharmaceutical industry and accumulate more than 2,500 enterprises.

Qiantang District’s superior business environment, high level of openness to the outside world, and robust digital economy, along with its long-term goal of building an ecosystem for the life and health industry, align perfectly with Pfizer’s consistent corporate mission of “delivering breakthroughs that change patients’ lives.” This alignment has motivated Pfizer to establish its presence in the district. The current conference serves as a concrete example of collaboration between Pfizer and Qiantang District, aiming to better facilitate communication, cooperation, and project implementation among all stakeholders in the ecosystem.

VCBeat, rooted in the industry, can only observe the tip of the iceberg of its strategy. The strategic deployment of Pfizer China’s digital innovation requires all stakeholders in the industry to personally explore and analyze it...